Free Trial

Enliven Therapeutics (ELVN) SEC Filings & 10K Form

Enliven Therapeutics logo
$22.47 -0.40 (-1.75%)
(As of 12/20/2024 05:16 PM ET)

Recent Enliven Therapeutics SEC Filings

DateFilerForm TypeView
12/16/2024
3:15 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
4:18 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/15/2024
3:28 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
4:46 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G/A
11/14/2024
4:48 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
Form SC 13G/A
11/14/2024
3:24 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G/A
11/13/2024
4:55 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SC 13G
11/13/2024
3:15 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/08/2024
1:17 PM
BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G
10/30/2024
5:04 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2024
1:02 PM
BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G
10/22/2024
3:18 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:19 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:21 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:22 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:23 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:17 PM
Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
5:42 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:27 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:42 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:10 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:17 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:57 PM
Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:00 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
4:06 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
3:38 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/10/2024
7:36 PM
Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2024
7:38 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2024
7:39 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2024
3:27 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/09/2024
3:16 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/08/2024
5:54 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
5:56 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
5:57 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
5:58 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2024
3:28 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/03/2024
5:43 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
5:44 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
5:45 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
5:47 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2024
6:53 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

09/30/2024
3:19 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/18/2024
3:17 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2024
4:43 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2024
5:36 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2024
6:48 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2024
6:49 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2024
3:32 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2024
3:32 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2024
3:15 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/02/2024
6:23 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/02/2024
6:25 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/02/2024
6:26 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/02/2024
6:22 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2024
6:31 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2024
6:33 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2024
3:30 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/31/2024
3:31 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/29/2024
5:12 PM
5AM Ventures VI, L.P. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13D/A
07/29/2024
4:39 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2024
3:15 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/25/2024
3:08 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/17/2024
6:25 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2024
4:37 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2024
4:34 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2024
3:12 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/12/2024
3:48 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/12/2024
3:48 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/03/2024
3:31 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2024
7:03 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2024
3:35 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2024
3:38 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/25/2024
2:08 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/20/2024
6:20 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2024
4:12 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
3:24 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/10/2024
5:46 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2024
4:54 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2024
4:56 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2024
3:06 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K/A
05/29/2024
3:08 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2024
4:45 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2024
4:29 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2024
6:46 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
4:03 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Gupta Rishi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/17/2024
2:08 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/17/2024
2:11 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED CAPITAL LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/17/2024
2:04 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/16/2024
6:29 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
4:23 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/16/2024
4:23 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

05/14/2024
3:15 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2024
3:10 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/13/2024
6:35 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2024
7:40 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2024
5:58 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2024
6:02 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2024
6:04 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/30/2024
11:15 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form EFFECT
04/30/2024
3:16 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 424B3
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners